ArticleOncogene2005
Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 67 citations in OpenAlex.
- Rasgrp1-Mediated Dampening of EGFR Signals Supports Coordinated Mammary Gland Development.Cells · 2026Article
- DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer.NPJ breast cancer · 2025Article
- Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model.Oncogene · 2024Article
- HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth.Vaccines · 2024Article
- HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.The Journal of cell biology · 2024Article
- The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.Frontiers in physiology · 2024Review
- ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author.Journal of mammary gland biology and neoplasia · 2023Review
- A requirement for p120-catenin in the metastasis of invasive ductal breast cancer.Journal of cell science · 2021Article
- Embryonic lethality and defective mammary gland development of activator-function impaired conditional knock-inAdvanced genetics (Hoboken, N.J.) · 2021Article
- RNA-Seq Reveals the Expression Profiles of Long Non-Coding RNAs in Lactating Mammary Gland from Two Sheep Breeds with Divergent Milk Phenotype.Animals : an open access journal from MDPI · 2020Article
- Unraveling Heterogeneity in Epithelial Cell Fates of the Mammary Gland and Breast Cancer.Cancers · 2019Review
- The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis.Development (Cambridge, England) · 2017Article
- CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.PLoS genetics · 2017Article
- Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.International journal of cancer · 2017Review
- Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland.PLoS genetics · 2014Article
- Article
- Cancer stem cells and cells of origin in MMTV-Her2/neu-induced mammary tumorigenesis.Oncogene · 2013Article
- HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.Cancer research · 2012Article
- p120-catenin is essential for terminal end bud function and mammary morphogenesis.Development (Cambridge, England) · 2012Article
- The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.